TransCode Therapeutics, Inc.
- RNAZ
- NASDAQ
- Biotechnology
- Metastatic Cancer Therapeutics
- RNA-Based Oncology
$1.70
Today −5.56%Quote Oct 16, 2026, 08:00 PM UTC
−1.16%over the last month
Max drawdown −12.4%From 1-month high −8.6%3 months −80.5%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$28.8M
Quote Oct 16
Next earnings
Nov 18
Expected, not confirmed
Latest analyst target
—
Data unavailable
Floor
$1.63
4.1% below price
Where the price sits
No analyst target range for this stock.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about RNAZPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
12